Clinical trial · Observational
Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung
Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung (The PRACTICAL Study)
NCT07202260CI-TRIAL-00096053PRACTICALactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study focuses on improving care for people with lung cancer who face unusual or complex treatment situations.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer (NSCLC) | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
| Lung Cancer (SCLC) | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (5)
- label
- Patients with co-existing interstitial lung disease
- label
- Patients who undergo radiotherapy twice to the same area (reirradiation).
- label
- Patients with the less common or rare types of lung cancer
- label
- Patients with cancer invading large blood vessels.
- label
- Patients with oligopersistent/oligoprogressive disease on immunotherapy or targeted therapies.
Primary outcomes (1)
- measure
- Acute and late toxicity
- timeFrame
- 2 years
- description
- \- Acute (\<90 days post radiotherapy) and late (\> 90 days post radiotherapy) toxicity according to common terminology criteria for adverse events (CTCAE) V5.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Complex patients with lung cancer undergoing radiotherapy in one of the following groups; * Rare histology * Disease invading vascular structures * Co-existing interstitial lung disease (ILD) * Radical re-irradiation * Oligopersistent/oligoprogressive disease on immunotherapy or targeted therapies. Exclusion Criteria: * Include patients with stage IV disease who are receiving non-curative intent radiotherapy * There are no exclusion criteria relating to upper age limit or comorbidities.
References
Publications (0)
Data not yet available
No reference posted for this study.